Corcept Therapeutics Says Data Shows Clinical Improvement

by Paul Quintaro, Benzinga Editor
April 9, 2012 12:47 PM | 12 seconds read |
Corcept Therapeutics Incorporated CORT today announced the results of its phase 3 SEISMIC trial published in The Journal of Clinical Endocrinology and Metabolism demonstrated that refractory Cushing's syndrome patients receiving Korlym experienced significant clinical improvement.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!